Vericel (NASDAQ:VCEL) Stock: Insider Robert Md Zerbe Sells 3,000 Shares

Vericel Corporation (NASDAQ:VCEL) Director Robert Md Zerbe sold 3,000 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $52.23, for a total value of $156,690.00. Following the completion of the sale, the director directly owned 32,995 shares in the company, valued at approximately $1,723,328.85. The trade was a 8.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Vericel Price Performance

VCEL opened at $54.62 on Friday. The stock has a market capitalization of $2.80 billion, a price-to-earnings ratio of 85.35 and a beta of 1.08. The business has a 50-day moving average of $41.01 and a two-hundred day moving average of $38.90. Vericel Corporation has a 12 month low of $28.95 and a 12 month high of $55.60.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.21. The business had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. Vericel had a net margin of 10.27% and a return on equity of 9.09%. The company’s revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 EPS. Equities research analysts anticipate that Vericel Corporation will post 0.54 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently commented on VCEL. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Vericel in a research report on Thursday, October 29th. HC Wainwright lifted their price target on shares of Vericel from $72.00 to $75.00 and gave the company a “buy” rating in a report on Friday. Canaccord Genuity Group set a $60.00 price objective on shares of Vericel in a research note on Thursday, July 30th. TD Cowen upped their price objective on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Truist Financial set a $65.00 target price on shares of Vericel in a research report on Friday. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $60.80.

Institutional Investors Weigh In On Vericel

Hedge funds and other institutional investors have recently bought and sold shares of the business. Lisanti Capital Growth LLC bought a new position in Vericel during the 2nd quarter valued at $5,356,000. Man Group plc acquired a new position in Vericel during the 2nd quarter worth $2,998,000. Scholtz & Company LLC acquired a new position in Vericel during the 2nd quarter worth $2,287,000. Bank of New York Mellon Corp bought a new stake in shares of Vericel in the 2nd quarter worth about $12,366,000. Finally, Madison Asset Management LLC bought a new stake in shares of Vericel in the 2nd quarter worth about $2,230,000.

Trending Headlines about Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.